Product Information

GLYPRESSIN® Solution for Injection

NAME OF THE MEDICINE

Terlipressin (as terlipressin acetate). The chemical name is $N\cdot[N\cdot(N\cdotGlycylglycyl)glycyl]-8-L$-lysinevasopressin.

Terlipressin has an empirical formula of $C_{52}H_{74}N_{16}O_{15}S_2$ and a molecular weight of 1227.4. CAS No: 14636-12-5. The pKa is approximately 10.

Terlipressin is freely soluble in water. Although the active ingredient is terlipressin, the drug substance included in this product contains non-stoichiometric amounts of acetic acid and water, and this material is freely soluble in water.

The structural formula of terlipressin is

$$H\cdotGly^1\cdotGly^2\cdotGly^3\cdotCys^4\cdot\text{Tyr}^5\cdot\text{Phe}^6\cdot\text{Gln}^7\cdot\text{Asn}^8\cdot\text{Cys}^9\cdot\text{Pro}^{10}\cdot\text{Lys}^{11}\cdot\text{Gly}^{12}\cdot\text{NH}^2$$

DESCRIPTION

GLYPRESSIN is for intravenous injection.

It consists of a clear, colourless liquid containing 0.85 mg terlipressin (equivalent to 1 mg terlipressin acetate) in 8.5 mL solution in an ampoule. The concentration of terlipressin is 0.1 mg/mL (equivalent to terlipressin acetate 0.12 mg/mL).

List of excipients

GLYPRESSIN contains the following excipients:

Sodium chloride, acetic acid, sodium acetate trihydrate, Water for Injections

PHARMACOLOGY

Pharmacodynamics

Terlipressin belongs to the pharmacotherapeutic group: Posterior pituitary lobe hormones (vasopressin and analogues), ATC code: H 01 BA 04.

Terlipressin is a dodecapeptide that has three glycyl residues attached to the N-terminal of lysine vasopressin (LVP). Terlipressin acts as a pro-drug and is converted via enzymatic cleavage of its three glycyl residues to the biologically active lysine vasopressin.

A large body of evidence has consistently shown that terlipressin given at doses of 0.85 mg and 1.7 mg respectively (equivalent to terlipressin acetate 1 mg and 2 mg respectively) can effectively reduce the portal venous pressure and produces marked vasoconstriction. The lowering of portal pressure and azygos blood flow is dependent on dose. The effect of the low dose is reduced after 3 hours, while haemodynamic data show that 1.7 mg terlipressin (2 mg terlipressin acetate) is more effective than 0.85 mg (1 mg terlipressin acetate), as the higher dose produces a dependable effect throughout the period of treatment (4 hours).

The primary pharmacodynamic effects of terlipressin are the vasoconstrictive effects mediated through V1a receptors on vascular smooth muscle in the splanchnic and portal circulation.
Moreover, terlipressin can also act via V₁₉ receptors to increase systemic mean arterial pressure and cause a reflexogenic heart rate reduction. Regarding secondary pharmacodynamic effects, terlipressin has shown minimal effects on the fibrinolytic system in cirrhotic patients acting on V₂ receptors. V₂ mediated antidiuretic effects have been observed with terlipressin corresponding to 3% of the native vasopressin. No consistent effect on serum sodium has been seen in healthy volunteers but there may be a potential risk for hyponatremia associated with terlipressin when treating patients with portal hypertension and actively bleeding oesophageal varices. No influence of V₁b receptors has been observed as illustrated by no significant effects observed on adrenocorticotropic hormone and cortisol release.

**Pharmacokinetics**

The pharmacokinetic properties of terlipressin have been investigated in healthy volunteers and in cirrhotic patients, with similar PK characteristics observed in both populations. The intravenous pharmacokinetic profile can be described using a two-compartment model with a distribution and elimination half-life of approximately 8 and 40 minutes, respectively. The kinetics of terlipressin is linear with a plasma clearance of about 9 mL/kg/min and a volume of distribution of 0.5 L/kg.

The estimated concentrations of lysine-vasopressin show an initial appearance in plasma 30 minutes after administration of terlipressin with a peak concentration occurring between 60 and 120 minutes. Terlipressin has also been found to be distributed to ascitic fluid, reaching equilibrium with plasma after 60 min.

About 1% of the dose administered was excreted unchanged in the urine which indicates almost complete metabolism by peptidases.

Because of a 100% cross-reactivity there is no available RIA-method to differentiate terlipressin from lysine-vasopressin.

**CLINICAL TRIALS**

The data evaluated for this indication were from a literature-based submission which uncovered 28 efficacy publications, including 8 that were published since the 2003 Cochrane Review. Several pharmacokinetic and dose ranging studies were also provided. Twenty-two other publications as well as post-marketing reports and a 1991 paper on post-marketing experience, and 127 literature references were also included.

The studies that contribute the most to demonstrating the efficacy of terlipressin in bleeding oesophageal varices are four pivotal, placebo-controlled studies (Walker et al, 1986; Freeman et al, 1989; Söderlund et al, 1990; Levacher et al, 1995) and two supportive, controlled studies involving endoscopic treatment (Escorsell et al 2000; Abid et al, 2009). Several other controlled studies provide further supportive evidence. In both the pivotal and supporting studies there was a consistently high rate of bleeding control with terlipressin, despite substantial differences in study design, the dose used and assessment of treatment effect.

All doses in the clinical trials section below are stated as 1 mg or 2 mg terlipressin to mean 1 mg or 2 mg terlipressin acetate.

**Placebo-controlled studies**

The study of Walker et al. (1986) was a randomised, double-blind, placebo-controlled study of terlipressin as an addition to standard therapy, in cirrhotic patients with endoscopically verified variceal bleeding. After endoscopy, patients were randomised to treatment with either an initial 2 mg i.v. injection of terlipressin, followed by a 1 mg injection every 4 h for a total of 36 h of treatment, or to corresponding placebo. A total of 50 bleeding episodes in 34 patients were randomised; all re-randomised patients had been discharged between randomisations.

The primary efficacy endpoint of control of bleeding within 36 h was met in 25/25 (100%) of the
episodes randomised to terlipressin, compared to 20/25 (80%) of the episodes randomised to placebo (p <0.05). A total of 5/25 (20%) of the episodes randomised to terlipressin were considered treatment failures (including episodes requiring balloon tamponade or sclerotherapy), in contrast to 12/25 (48%) episodes randomised to placebo (p <0.05). There were no statistically significant differences between the treatment groups in the secondary endpoints of blood and plasma transfusion requirements, duration of bleeding, rebleeding after 36 h of treatment, or in-hospital mortality (terlipressin: 3 deaths/25 episodes, 12%; placebo: 8 deaths/25 episodes, 32%, n.s.).

The study of Freeman et al. (1989) was a randomised, double-blind, placebo-controlled study of terlipressin in patients with portal hypertension and endoscopically verified variceal bleeding. After endoscopy, patients were randomised to treatment with either an initial 2 mg i.v. injection of terlipressin, followed by a 2 mg injection every 4 h for a total of 24 h of treatment (or at least 8 h after the bleeding stopped), then a 1 mg injection every 4 h for an additional 16 h; or to corresponding placebo. A total of 31 bleeding episodes in 29 patients were randomised.

The primary efficacy endpoint of initial control of bleeding without the need for balloon tamponade/rescue sclerotherapy was met in 9/15 (60%) of the episodes randomised to terlipressin, compared to 6/16 (37%) of the episodes randomised to placebo (n.s.). During follow-up, 1 patient in the terlipressin group and 3 patients in the placebo group had rebleedings (all were successfully controlled by rescue sclerotherapy), leaving 8/15 (53%) of the episodes randomised to terlipressin and 3/16 (19%) of the episodes randomised to placebo as being successfully controlled at 5 days (secondary endpoint; p <0.05). There were no statistically significant differences between the treatment groups in the further secondary endpoints of blood transfusion requirement or in-hospital mortality (terlipressin: 3 deaths/15 episodes, 20%; placebo: 4 deaths/16 episodes, 25%).

The study of Söderlund et al. (1990) was a randomised, double-blind, placebo-controlled study of terlipressin in cirrhotic patients with endoscopically verified variceal bleeding. After endoscopy, patients were randomised to treatment with either an initial 2 mg i.v. injection of terlipressin, followed by a 2 mg injection every 4 h for a total of 24 to 36 h of treatment, or to corresponding placebo. Treatment was discontinued with a control endoscopy (including sclerotherapy) between 24 and 36 h after the initiation of treatment, or until emergency intervention (e.g. balloon tamponade) was required. A total of 60 patients were randomised; no patient was randomised more than once.

The primary efficacy endpoint of initial control of bleeding without emergency intervention ('success') was met in 28/31 (90%) of the patients randomised to terlipressin, and in 17/29 (59%) of the patients randomised to placebo (p=0.0067; Fisher's exact test). During treatment, 2 patients in the terlipressin group and 1 patient in the placebo group had rebleedings, thus the secondary endpoint of ‘efficacy’ (defined as absence of blood in two consecutive gastric rinses, and no ongoing bleeding/fresh blood at control endoscopy) was met in 26/31 (84%) of the patients in the terlipressin group and in 16/29 (55%) of the patients in the placebo group (p=0.024; Fisher’s exact test). During treatment, transfusion requirements were statistically significantly lower in the terlipressin group than in the placebo group. During the whole study, from first injection to 24-hour follow-up, 22/31 (71%) of the patients in the terlipressin group and 28/29 (97%) of the patients in the placebo group required any blood transfusion (p <0.05). In-hospital mortality was 3/31 (10%) of the patients in the terlipressin group and 11/29 (38%) of the patients in the placebo group (p <0.05).

The study of Levacher et al. (1995) was a randomised, double-blind, placebo-controlled study of the combination of terlipressin and nitroglycerin, in cirrhotic patients with upper GI bleeding as diagnosed by gastric lavage. Patients were randomised by an emergency team in the home setting, to treatment with either terlipressin (an initial injection of 1 mg for patients <50 kg, 1.5 mg for patients 50-70 kg, or 2 mg for patients >70 kg; patients received repeat injections at 4 h and 8 h) and a transdermal nitroglycerin patch (24 mg/12 h), or to corresponding placebo injections and excipient patch. After initiation of treatment, patients were transferred to the hospital intensive care unit. Concurrent treatments in both treatment groups included endoscopic sclerotherapy, but this was not necessarily performed before the primary efficacy evaluation (control of bleeding at 12 h).
A total of 85 bleeding episodes in 77 patients were randomised; all re-randomised patients had at least 30 days between bleeding episodes. One patient had been included by 'error', therefore the analysis was performed on 84 bleeding episodes in 76 patients.

The primary efficacy endpoint of control of bleeding (without rebleeding) at 12 h was met in 29/41 (71%) of the episodes randomised to terlipressin, and in 20/43 (47%) of the episodes randomised to placebo (p <0.05). There was no statistically significant difference between the treatment groups in the secondary endpoint of frequency of rebleeding after 12 h; however, the episodes randomised to terlipressin required fewer blood transfusions than episodes randomised to placebo (a mean of 0.79 versus 1.9 units/day; p <0.05). Mortality was lower in the episodes randomised to terlipressin than in those randomised to placebo at 15 days (8/41, 20% vs. 18/43, 42%; p <0.05) but not at 42 days (12/41, 36% vs. 20/43, 47%; n.s.). When adjusting for Child-Pugh class, the difference in mortality was statistically significant in favour of terlipressin also at 42 days; in all episodes not classified as Child-Pugh C, the patient survived.

Study versus endoscopic treatment
The study of Escorsell et al. (2000) was a randomised, non-blinded study of terlipressin versus endoscopic sclerotherapy in cirrhotic patients with endoscopically verified bleeding oesophageal varices. During diagnostic endoscopy, patients were randomised to treatment with either terlipressin (initial 2 mg i.v. injection followed by 2 mg injections every 4 h for 48 h or until control of bleeding was achieved, followed by 1 mg injections every 4 h for 5 more days) or endoscopic sclerotherapy (one immediate intra-paravariceal injection of 5% ethanolamine or 1% polidocanol; no further sclerotherapy until at least one study endpoint was reached). A total of 219 patients were randomised; no patient was randomised more than once.

The primary efficacy endpoint of initial control of bleeding within 48 h was met in 85/105 (81%) patients randomised to terlipressin and in 94/114 (82%) of the patients randomised to sclerotherapy (n.s.). The secondary endpoint of early rebleeding (within 5 days) occurred in 15 patients (14%) in the terlipressin group and in 16 patients (14%) in the sclerotherapy group (n.s.). There were no statistically significant differences between the treatment groups in transfusion requirements, length of hospitalisation (including ICU stay), need for alternative therapy, or the frequency of late rebleeding (terlipressin, 26/105 patients, 25%; sclerotherapy, 29/114 patients, 25%). The 42-day mortality rates were similar between treatment groups (terlipressin, 29/105 patients, 28%; sclerotherapy, 19/114 patients, 17%; n.s).

Study versus active comparator, in addition to endoscopic treatment
The study of Abid et al. (2009) was a randomised, double-blind non-inferiority study of terlipressin or octreotide as additions to endoscopic banding ligation, in cirrhotic patients with endoscopically verified oesophageal variceal bleeding. On admission but before diagnostic endoscopy, patients were randomised to treatment with either terlipressin (initial 2 mg i.v. injection followed by 1 mg injections every 6 h for a total of 72 h of treatment) or with octreotide (initial 100 μg i.v. injection and 50 μg/h infusion for a total of 72 h); both treatment groups received mock placebo treatments. All patients had endoscopic banding ligation within 24 h. A total of 359 patients were randomised before diagnostic endoscopy. Of these patients, 35 were excluded from analysis due to violation of inclusion/exclusion criteria. Thus, 324 patients with endoscopically confirmed oesophageal variceal bleeding were included in the ITT analysis.

The primary efficacy endpoint of control of bleeding (according to Baveno III criteria) within 72 h was was met in 158/163 (97%) of the patients randomised to terlipressin + banding ligation, and in 160/161 (99%) of the patients randomised to octreotide + banding ligation (n.s.). Based on a prespecified non-inferiority margin of 11% for the lower limit of the 95% confidence interval, it was concluded that terlipressin + banding ligation was non-inferior to octreotide + banding ligation. The mean length of hospitalisation was shorter in the terlipressin group than in the octreotide group (108 h vs. 126 h, p <0.001). In-hospital mortality was 9/163 (6%) in the terlipressin group and 7/161 (4%) in the octreotide group (n.s.).

Duration of treatment
In the placebo-controlled studies, treatment duration up to the primary efficacy endpoint varied between 12 h and 36 h. The maximum duration of treatment with 2 mg doses (given either every 4 hours or every 6 hours) in any of the evaluated studies was 48 hours (see DOSAGE AND ADMINISTRATION). In those studies where treatment was continued for up to 5 days, a 1 mg dose was used for some or all of the dosing period. A consensus statement from the fifth Baveno Congress (Baveno V) recommends treatment for up to 5 days.

INDICATIONS

GLYPRESSIN is indicated for the treatment of bleeding oesophageal varices.

CONTRAINDICATIONS

Pregnancy.
Hypersensitivity to terlipressin or any other excipients of the product.

PRECAUTIONS

Cardiovascular Effects
Terlipressin should only be used with caution and under strict monitoring of the patients in the following cases:
- uncontrolled hypertension
- cerebral or peripheral vascular diseases
- cardiac arrhythmias
- coronary artery disease or previous myocardial infarction

Terlipressin should not be used in patients with unstable angina or recent acute myocardial infarction.

During post-marketing experience, cases of QT interval prolongation and ventricular arrhythmias including "Torsade de pointes" have been reported. In most cases, patients had predisposing factors such as basal prolongation of the QT interval, electrolyte abnormalities (hypokalemia, hypomagnesemia) or medications with concomitant effect on QT prolongation. Therefore, extreme caution should be exercised in the use of terlipressin in patients with a history of QT interval prolongation, electrolytic abnormalities, concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that can cause hypokalaemia or hypomagnesemia (e.g. some diuretics) (see INTERACTIONS).

Ischaemic Events
To avoid local necrosis the injection must be administered intravenously.

During post-marketing experience several cases of cutaneous ischemia and necrosis unrelated to the injection site have been reported. Patients with peripheral venous hypertension or morbid obesity seem to have a greater tendency to this reaction. Therefore, extreme caution should be exercised when administering terlipressin in these patients.

Respiratory Effects
Terlipressin may cause smooth muscle constriction and should be used with caution and under strict monitoring in patients with severe asthma or chronic obstructive pulmonary disease (COPD).

Laboratory Monitoring
During treatment with terlipressin serum creatinine should be monitored at least daily as terlipressin should be used with caution in patients with renal insufficiency.
Fluid balance and electrolytes should be monitored carefully as hyponatraemia, hypokalaemia, hypomagnesaemia and other electrolyte disturbances have been reported.

**Children and the Elderly**
Because of limited experience, special precaution should be taken during treatment of children and elderly patients. No data are available regarding dosage recommendation in these special patient categories.

**Renal Impairment**
As data are limited terlipressin should be used with caution and under strict monitoring of the patients in renal impairment.

**Effects on fertility**
There are no human data on the effects of terlipressin on male or female fertility. In a rat fertility study, mating of terlipressin-treated males (3 weeks prior to mating at 1.8 and 3.6 mg/m²/day IV; ca. 25-50% of the Maximum Recommended Daily Human Dose) with untreated females had no effect on the number of matings and frequency of insemination but led to decreased litter size. In a separate study, testicular atrophy and disturbances of spermiogenesis were observed in male rats treated with terlipressin for 3 weeks at 3.6 mg/m²/day IV. Based on animal studies, there is some risk of reduced fertility in persons taking terlipressin.

**Use in Pregnancy (Category D)**
Treatment with terlipressin is contraindicated in pregnancy.

Terlipressin is known to cause uterine contractions and increased intrauterine pressure in early pregnancy and may decrease uterine blood flow in humans. Terlipressin may have harmful effects on the pregnancy and the fetus.

Spontaneous abortion and fetal malformations were observed in pregnant rabbits treated with terlipressin throughout organogenesis at IV doses (based on body surface area) less than the maximum recommended human daily dose.

**Use in Lactation**
There are no human or animal data on the excretion of terlipressin into milk or on the safety of terlipressin in infants. Hence, terlipressin should not be used in women who are breast-feeding.

**Genotoxicity**
Assays for gene mutation and chromosomal damage did not provide any evidence of a genotoxic potential for terlipressin.

**Carcinogenicity**
Carcinogenicity studies have not been performed.

**INTERACTION WITH OTHER MEDICINES**
Terlipressin increases the hypotensive effect of non-selective β-blockers on the portal vein. Concomitant treatment with drugs which are known to induce bradycardia (e.g. propofol, sufentanil) may lower the heart rate and cardiac output. These effects are due to reflexogenic inhibition of cardiac activity via the vagus nerve due to elevated blood pressure.

Terlipressin can trigger ventricular arrhythmias including "Torsade de pointes" (see PRECAUTIONS and ADVERSE EFFECTS). Therefore, extreme caution should be exercised in the use of terlipressin in patients with concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that may cause hypokalaemia or hypomagnesemia (e.g. some diuretics).
ADVERSE EFFECTS

The reporting of safety data rely on published literature and post marketing surveillance.

Clinical Trials

Three studies assessed safety as primary outcome in totally 1341 patients.

Caletti 1991, a prospective, uncontrolled observational study, enrolled 1258 patients. 21% of the patients experienced a side-effect. The side-effects reported were consistent with the known pharmacological actions of terlipressin.

Bruha 2009, a randomised, double blind study enrolled 25 patients that were randomised to either 5-day or 10- day treatment. Serum sodium and serum creatinine decreased in both arms during treatment, but rose again after discontinuation of treatment.

Solà 2010, a retrospective cohort study, included 58 patients. Over a 5 day treatment period 67% of the patients developed acute reduction in serum sodium. The hyponatraemia was found to develop rapidly after start of therapy, but was usually reversible with a median recovery time of 4 days after discontinuation of terlipressin.

Post-marketing Experience

The most commonly reported affected system organ classes were: cardiac disorders (66 reactions); vascular disorders (50 reactions); skin and subcutaneous tissue disorders (34 reactions); gastrointestinal disorders (30 reactions); metabolism and nutrition disorders (26 reactions) and nervous system disorders (22 reactions).

The table below lists the adverse effects reported for terlipressin in the post-marketing period.

<table>
<thead>
<tr>
<th>MedDRA System organ class Disorder</th>
<th>Common (≥1% &amp; &lt;10%)</th>
<th>Uncommon (≥0.1% &amp; &lt;1%)</th>
<th>Rare (≥0.01% &amp; &lt;0.1%)</th>
<th>Not known (cannot be estimated from the available data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>METABOLISM</td>
<td>Hyponatraemia if fluid not monitored;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td>Headache;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARDIAC</td>
<td>Bradycardia;</td>
<td>Atrial Fibrillation;</td>
<td>Ventricular fibrillation;</td>
<td>Torsade de pointes; Cardiac failure;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ventricular Extrasystoles;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachycardia;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chest pain;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Myocardial Infarction;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fluid overload with pulmonary oedema;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VASCULAR</td>
<td>Peripheral vasoconstriction; Peripheral ischemia; Facial pallor; Hypertension;</td>
<td>Intestinal ischaemia; Peripheral cyanosis; Hot flushes;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RESPIRATORY</td>
<td>Respiratory distress;</td>
<td></td>
<td>Dyspnoea;</td>
<td></td>
</tr>
<tr>
<td>GASTROINTESTINAL</td>
<td>Transient abdominal cramps; Transient diarrhoea;</td>
<td>Transient nausea; Transient vomiting;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SKIN AND SUBCUTANEOUS</td>
<td></td>
<td></td>
<td></td>
<td>Skin necrosis;</td>
</tr>
<tr>
<td>PREGNANCY, Puerperium and Perinatal Conditions</td>
<td></td>
<td></td>
<td></td>
<td>Uterine hypertonus; Decrease uterine blood flow;</td>
</tr>
<tr>
<td>GENERAL</td>
<td>Injection site necrosis;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
DOSAGE AND ADMINISTRATION

GLYPRESSIN must only be administered intravenously.

Adults:
Initially an i.v. injection of 1.7 mg terlipressin (2 mg terlipressin acetate) is given every 4 hours. When the bleeding is under control the dose can be adjusted to 0.85 mg terlipressin (1 mg terlipressin acetate) i.v. every 4 hours. After the initial dose, the dose can also be adjusted to 0.85 mg (1 mg terlipressin acetate) i.v. every 4 hours in patients with body weight < 50 kg or if adverse effects occur. The treatment should not continue for more than 48 hours in total.

Children and Elderly:
No data are available regarding dosage recommendations in these patient populations.

OVERDOSAGE

The recommended dose of 1.7 mg (equivalent to 2 mg terlipressin acetate) every 4 hours should not be exceeded as the risk of severe circulatory adverse effects is dose-dependent.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

PRESENTATION AND STORAGE CONDITIONS

GLYPRESSIN Solution for Injection, ampoule:
8.5 mL clear, colourless solution in clear glass ampoule, containing 0.85 mg terlipressin (equivalent to 1 mg terlipressin acetate). Supplied in box containing 5 ampoules.

Storage conditions
Store in a refrigerator at 2°C - 8°C in the outer carton to protect from light.

NAME AND ADDRESS OF SPONSOR

Ferring Pharmaceuticals Pty Ltd
Suite 2, Level 1, Building 1
20 Bridge Street
Pymble NSW 2073
Australia

POISON SCHEDULE OF THE MEDICINE

Prescription Medicine (Schedule 4)

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (the ARTG)
14 May 2012

DATE OF MOST RECENT AMENDMENT
References:
Abid et al 2009:

Baveno V:
de Franchis, R (BAVENO V);

Bruha 2009:

Caletti 1991:

Escorsell et al 2000:

Freeman et al 1989:

Levacher et al 1995:

Söderlund et al 1990:

Solà 2010:

Walker et al 1986:
Product Information

GLYPRESSIN® Powder for Injection

NAME OF THE MEDICINE
Terlipressin (as terlipressin acetate). The chemical name is \( N-[N-(N\text{-Glycylglycyl})\text{glycyl}]-8-L\text{-lysine}\text{vasopressin} \).

Terlipressin has an empirical formula of \( C_{52}H_{74}N_{16}O_{15}S_{2} \) and a molecular weight of 1227.4. CAS No: 14636-12-5. The pKa is approximately 10.

Terlipressin is freely soluble in water. Although the active ingredient is terlipressin, the drug substance included in this product contains non-stoichiometric amounts of acetic acid and water, and this material is freely soluble in water.

The structural formula of terlipressin is

\[
\text{H-Gly}^1\text{-Gly}^2\text{-Gly}^3\text{-Cys}^4\text{-Tyr}^5\text{-Phe}^6\text{-Gln}^7\text{-Asn}^8\text{-Cys}^9\text{-Pro}^{10}\text{-Lys}^{11}\text{-Gly}^{12}\text{-NH}_2
\]

DESCRIPTION
GLYPRESSIN is for intravenous injection.

It consists of one vial containing 0.85 mg terlipressin (equivalent to 1 mg terlipressin acetate), as a sterile, white, fluffy, lyophilised powder, supplied with a 5 mL ampoule containing a clear, colourless diluent consisting of 0.9% sodium chloride (pH 3.2). The powder is reconstituted immediately before use. The concentration of the reconstituted solution is 0.17 mg terlipressin per mL (equivalent to 0.2 mg terlipressin acetate per mL).

List of Excipients
GLYPRESSIN powder vial: Mannitol, Hydrochloric acid
Diluent ampoule: Sodium chloride, Hydrochloric acid, Water for Injections

PHARMACOLOGY
Pharmacodynamics
Terlipressin belongs to the pharmacotherapeutic group: Posterior pituitary lobe hormones (vasopressin and analogues), ATC code: H 01 BA 04.

Terlipressin is a dodecapeptide that has three glycyl residues attached to the N-terminal of lysine vasopressin (LVP). Terlipressin acts as a pro-drug and is converted via enzymatic cleavage of its three glycyl residues to the biologically active lysine vasopressin.

A large body of evidence has consistently shown that terlipressin given at 0.85 mg and 1.7 mg respectively (equivalent to terlipressin acetate 1 mg and 2 mg respectively) can effectively reduce the portal venous pressure and produces marked vasoconstriction. The lowering of portal pressure and aygos blood flow is dose-dependent. The effect of the low dose is reduced after 3 hours, while haemodynamic data show that 1.7 mg terlipressin (2 mg terlipressin acetate) is more effective than 0.85 mg (1 mg terlipressin acetate), as the higher dose produces a dependable effect throughout the period of treatment (4 hours).

The primary pharmacodynamic effects of terlipressin are the vasoconstrictive effects mediated through \( V_{1a} \) receptors on vascular smooth muscle in the splanchic and portal circulation. Moreover, terlipressin can also act via \( V_{1a} \) receptors to increase systemic mean arterial pressure.
and cause a reflexogenic heart rate reduction. Regarding secondary pharmacodynamic effects, terlipressin has shown minimal effects on the fibrinolytic system in cirrhotic patients acting on V2 receptors. V2 mediated antidiuretic effects have been observed with terlipressin corresponding to 3% of the native vasopressin. No consistent effect on serum sodium has been seen in healthy volunteers but there may be a potential risk for hyponatremia associated with terlipressin when treating patients with portal hypertension and actively bleeding oesophageal varices. No influence of V1b receptors has been observed as illustrated by no significant effects observed on adrenocorticotropic hormone and cortisol release.

**Pharmacokinetics**

The pharmacokinetic properties of terlipressin have been investigated in healthy volunteers and in cirrhotic patients, with similar PK characteristics observed in both populations. The intravenous pharmacokinetic profile can be described using a two-compartment model with a distribution and elimination half-life of approximately 8 and 40 minutes, respectively. The kinetics of terlipressin is linear with a plasma clearance of about 9 mL/kg/min and a volume of distribution of 0.5 L/kg.

The estimated concentrations of lysine-vasopressin show an initial appearance in plasma 30 minutes after administration of terlipressin with a peak concentration occurring between 60 and 120 minutes. Terlipressin has also been found to be distributed to ascitic fluid, reaching equilibrium with plasma after 60 min.

About 1% of the dose administered was excreted unchanged in the urine which indicates almost complete metabolism by peptidases.

Because of a 100% cross-reactivity there is no available RIA-method to differentiate terlipressin from lysine-vasopressin.

**CLINICAL TRIALS**

The data evaluated for this indication were from a literature-based submission which uncovered 28 efficacy publications, including 8 that were published since the 2003 Cochrane Review. Several pharmacokinetic and dose ranging studies were also provided. Twenty-two other publications as well as post-marketing reports and a 1991 paper on post-marketing experience, and 127 literature references were also included.

The studies that contribute the most to demonstrating the efficacy of terlipressin in bleeding oesophageal varices are four pivotal, placebo-controlled studies (Walker et al, 1986; Freeman et al, 1989; Söderlund et al, 1990; Levacher et al, 1995) and two supportive, controlled studies involving endoscopic treatment (Escorsell et al 2000; Abid et al, 2009). Several other controlled studies provide further supportive evidence. In both the pivotal and supporting studies there was a consistently high rate of bleeding control with terlipressin, despite substantial differences in study design, the dose used and assessment of treatment effect.

All doses in the clinical trials section below are stated as 1 mg or 2 mg terlipressin to mean 1 mg or 2 mg terlipressin acetate.

**Placebo-controlled studies**

The study of Walker *et al.* (1986) was a randomised, double-blind, placebo-controlled study of terlipressin as an addition to standard therapy, in cirrhotic patients with endoscopically verified variceal bleeding. After endoscopy, patients were randomised to treatment with either an initial 2 mg i.v. injection of terlipressin, followed by a 1 mg injection every 4 h for a total of 36 h of treatment, or to corresponding placebo. A total of 50 bleeding episodes in 34 patients were randomised; all re-randomised patients had been discharged between randomisations.

The primary efficacy endpoint of control of bleeding within 36 h was met in 25/25 (100%) of the episodes randomised to terlipressin, compared to 20/25 (80%) of the episodes randomised to placebo (p <0.05). A total of 5/25 (20%) of the episodes randomised to terlipressin were considered.
treatment failures (including episodes requiring balloon tamponade or sclerotherapy), in contrast to 12/25 (48%) episodes randomised to placebo (p <0.05). There were no statistically significant differences between the treatment groups in the secondary endpoints of blood and plasma transfusion requirements, duration of bleeding, rebleeding after 36 h of treatment, or in-hospital mortality (terlipressin: 3 deaths/25 episodes, 12%; placebo: 8 deaths/25 episodes, 32%, n.s.).

The study of Freeman et al. (1989) was a randomised, double-blind, placebo-controlled study of terlipressin in patients with portal hypertension and endoscopically verified variceal bleeding. After endoscopy, patients were randomised to treatment with either an initial 2 mg i.v. injection of terlipressin, followed by a 2 mg injection every 4 h for a total of 24 h of treatment (or at least 8 h after the bleeding stopped), then a 1 mg injection every 4 h for an additional 16 h; or to corresponding placebo. A total of 31 bleeding episodes in 29 patients were randomised.

The primary efficacy endpoint of initial control of bleeding without the need for balloon tamponade/rescue sclerotherapy was met in 9/15 (60%) of the episodes randomised to terlipressin, compared to 6/16 (37%) of the episodes randomised to placebo (n.s.). During follow-up, 1 patient in the terlipressin group and 3 patients in the placebo group had rebleedings (all were successfully controlled by rescue sclerotherapy), leaving 8/15 (53%) of the episodes randomised to terlipressin and 3/16 (19%) of the episodes randomised to placebo as being successfully controlled at 5 days (secondary endpoint; p <0.05). There were no statistically significant differences between the treatment groups in the further secondary endpoints of blood transfusion requirement or in-hospital mortality (terlipressin: 3 deaths/15 episodes, 20%; placebo: 4 deaths/16 episodes, 25%).

The study of Söderlund et al. (1990) was a randomised, double-blind, placebo-controlled study of terlipressin in cirrhotic patients with endoscopically verified variceal bleeding. After endoscopy, patients were randomised to treatment with either an initial 2 mg i.v. injection of terlipressin, followed by a 2 mg injection every 4 h for a total of 24 to 36 h of treatment, or to corresponding placebo. Treatment was discontinued with a control endoscopy (including sclerotherapy) between 24 and 36 h after the initiation of treatment, or until emergency intervention (e.g. balloon tamponade) was required. A total of 60 patients were randomised; no patient was randomised more than once.

The primary efficacy endpoint of initial control of bleeding without emergency intervention (‘success’) was met in 28/31 (90%) of the patients randomised to terlipressin, and in 17/29 (59%) of the patients randomised to placebo (p=0.0067; Fisher’s exact test). During treatment, 2 patients in the terlipressin group and 1 patient in the placebo group had rebleedings, thus the secondary endpoint of ‘efficacy’ (defined as absence of blood in two consecutive gastric rinses, and no ongoing bleeding/fresh blood at control endoscopy) was met in 26/31 (84%) of the patients in the terlipressin group and in 16/29 (55%) of the patients in the placebo group (p=0.024; Fisher’s exact test). During treatment, transfusion requirements were statistically significantly lower in the terlipressin group than in the placebo group. During the whole study, from first injection to 24-hour follow-up, 22/31 (71%) of the patients in the terlipressin group and 28/29 (97%) of the patients in the placebo group required any blood transfusion (p <0.05). In-hospital mortality was 3/31 (10%) of the patients in the terlipressin group and 11/29 (38%) of the patients in the placebo group (p <0.05).

The study of Levacher et al. (1995) was a randomised, double-blind, placebo-controlled study of the combination of terlipressin and nitroglycerin, in cirrhotic patients with upper GI bleeding as diagnosed by gastric lavage. Patients were randomised by an emergency team in the home setting, to treatment with either terlipressin (an initial injection of 1 mg for patients <50 kg, 1.5 mg for patients 50-70 kg, or 2 mg for patients >70 kg; patients received repeat injections at 4 h and 8 h) and a transdermal nitroglycerin patch (24 mg/12 h), or to corresponding placebo injections and excipient patch. After initiation of treatment, patients were transferred to the hospital intensive care unit. Concurrent treatments in both treatment groups included endoscopic sclerotherapy, but this was not necessarily performed before the primary efficacy evaluation (control of bleeding at 12 h). A total of 85 bleeding episodes in 77 patients were randomised; all re-randomised patients had at least 30 days between bleeding episodes. One patient had been included by ‘error’, therefore the
analysis was performed on 84 bleeding episodes in 76 patients.

The primary efficacy endpoint of control of bleeding (without rebleeding) at 12 h was met in 29/41 (71%) of the episodes randomised to terlipressin, and in 20/43 (47%) of the episodes randomised to placebo (p <0.05). There was no statistically significant difference between the treatment groups in the secondary endpoint of frequency of rebleeding after 12 h; however, the episodes randomised to terlipressin required fewer blood transfusions than episodes randomised to placebo (a mean of 0.79 versus 1.9 units/day; p <0.05). Mortality was lower in the episodes randomised to terlipressin than in those randomised to placebo at 15 days (8/41, 20% vs. 18/43, 42%; p <0.05) but not at 42 days (12/41, 36% vs. 20/43, 47%; n.s.). When adjusting for Child-Pugh class, the difference in mortality was statistically significant in favour of terlipressin also at 42 days; in all episodes not classified as Child-Pugh C, the patient survived.

**Study versus endoscopic treatment**

The study of Escorsell *et al.* (2000) was a randomised, non-blinded study of terlipressin versus endoscopic sclerotherapy in cirrhotic patients with endoscopically verified bleeding oesophageal varices. During diagnostic endoscopy, patients were randomised to treatment with either terlipressin (initial 2 mg i.v. injection followed by 2 mg injections every 4 h for 48 h or until control of bleeding was achieved, followed by 1 mg injections every 4 h for 5 more days) or endoscopic sclerotherapy (one immediate intra-paravariceal injection of 5% ethanolamine or 1% polidocanol; no further sclerotherapy until at least one study endpoint was reached). A total of 219 patients were randomised; no patient was randomised more than once.

The primary efficacy endpoint of initial control of bleeding within 48 h was met in 85/105 (81%) patients randomised to terlipressin and in 94/114 (82%) of the patients randomised to sclerotherapy (n.s.). The secondary endpoint of early rebleeding (within 5 days) occurred in 15 patients (14%) in the terlipressin group and in 16 patients (14%) in the sclerotherapy group (n.s.). There were no statistically significant differences between the treatment groups in transfusion requirements, length of hospitalisation (including ICU stay), need for alternative therapy, or the frequency of late rebleeding (terlipressin, 26/105 patients, 25%; sclerotherapy, 29/114 patients, 25%). The 42-day mortality rates were similar between treatment groups (terlipressin, 29/105 patients, 28%; sclerotherapy, 19/114 patients, 17%; n.s).

**Study versus active comparator, in addition to endoscopic treatment**

The study of Abid *et al.* (2009) was a randomised, double-blind non-inferiority study of terlipressin or octreotide as additions to endoscopic banding ligation, in cirrhotic patients with endoscopically verified oesophageal variceal bleeding. On admission but before diagnostic endoscopy, patients were randomised to treatment with either terlipressin (initial 2 mg i.v. injection followed by 1 mg injections every 6 h for a total of 72 h of treatment) or with octreotide (initial 100 μg i.v. injection and 50 μg/h infusion for a total of 72 h); both treatment groups received mock placebo treatments. All patients had endoscopic banding ligation within 24 h. A total of 359 patients were randomised before diagnostic endoscopy. Of these patients, 35 were excluded from analysis due to violation of inclusion/exclusion criteria. Thus, 324 patients with endoscopically confirmed oesophageal variceal bleeding were included in the ITT analysis.

The primary efficacy endpoint of control of bleeding (according to Baveno III criteria) within 72 h was met in 158/163 (97%) of the patients randomised to terlipressin + banding ligation, and in 160/161 (99%) of the patients randomised to octreotide + banding ligation (n.s.). Based on a prespecified non-inferiority margin of 11% for the lower limit of the 95% confidence interval, it was concluded that terlipressin + banding ligation was non-inferior to octreotide + banding ligation. The mean length of hospitalisation was shorter in the terlipressin group than in the octreotide group (108 h vs. 126 h, p <0.001). In-hospital mortality was 9/163 (6%) in the terlipressin group and 7/161 (4%) in the octreotide group (n.s.).

**Duration of treatment**

In the placebo-controlled studies, treatment duration up to the primary efficacy endpoint varied between 12 h and 36 h. The maximum duration of treatment with 2 mg doses (given every 4
hours or every 6 hours) in any of the evaluated studies was 48 hours (see DOSAGE AND ADMINISTRATION). In those studies where treatment was continued for up to 5 days, a 1 mg dose was used for some or all of the dosing period. A consensus statement from the fifth Baveno Congress (Baveno V) recommends treatment for up to 5 days.

INDICATIONS
GLYPRESSIN is indicated for the treatment of bleeding oesophageal varices.

CONTRAINDICATIONS
Pregnancy.
Hypersensitivity to terlipressin or any other excipients of the product.

PRECAUTIONS
Cardiovascular Effects
Terlipressin should only be used with caution and under strict monitoring of the patients in the following cases:
- uncontrolled hypertension
- cerebral or peripheral vascular diseases
- cardiac arrhythmias
- coronary artery disease or previous myocardial infarction

Terlipressin should not be used in patients with unstable angina or recent acute myocardial infarction.

During post-marketing experience, cases of QT interval prolongation and ventricular arrhythmias including "Torsade de pointes" have been reported. In most cases, patients had predisposing factors such as basal prolongation of the QT interval, electrolyte abnormalities (hypokalemia, hypomagnesemia) or medications with concomitant effect on QT prolongation. Therefore, extreme caution should be exercised in the use of terlipressin in patients with a history of QT interval prolongation, electrolytic anormalities, concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that can cause hypokalaemia or hypomagnesemia (e.g. some diuretics) (see INTERACTIONS).

Ischaemic Events
To avoid local necrosis the injection must be administered intravenously.

During post-marketing experience several cases of cutaneous ischemia and necrosis unrelated to the injection site have been reported. Patients with peripheral venous hypertension or morbid obesity seem to have a greater tendency to this reaction. Therefore, extreme caution should be exercised when administering terlipressin in these patients.

Respiratory Effects
Terlipressin may cause smooth muscle constriction and should be used with caution and under strict monitoring in patients with severe asthma or chronic obstructive pulmonary disease (COPD).

Laboratory Monitoring
During treatment with terlipressin serum creatinine should be monitored at least daily as terlipressin should be used with caution in patients with renal insufficiency.

Fluid balance and electrolytes should be monitored carefully as hyponatraemia, hypokalaemia, hypomagnesaemia and other electrolyte disturbances have been reported.

Children and the Elderly
Because of limited experience, special precaution should be taken during treatment of children and elderly patients. No data are available regarding dosage recommendation in these special patient categories.

Renal Impairment
As data are limited terlipressin should be used with caution and under strict monitoring of the patients in renal impairment.

Effects on Fertility
There are no human data on the effects of terlipressin on male or female fertility. In a rat fertility study, mating of terlipressin-treated males (3 weeks prior to mating at 1.8 and 3.6 mg/m²/day IV; ca. 25-50% of the Maximum Recommended Daily Human Dose) with untreated females had no effect on the number of matings and frequency of insemination but led to decreased litter size. In a separate study, testicular atrophy and disturbances of spermiogenesis were observed in male rats treated with terlipressin for 3 weeks at 3.6 mg/m²/day IV. Based on animal studies, there is some risk of reduced fertility in persons taking terlipressin.

Use in Pregnancy (Category D)
Treatment with terlipressin is contraindicated in pregnancy.

Terlipressin is known to cause uterine contractions and increased intrauterine pressure in early pregnancy and may decrease uterine blood flow in humans. Terlipressin may have harmful effects on the pregnancy and the fetus.

Spontaneous abortion and fetal malformations were observed in pregnant rabbits treated with terlipressin throughout organogenesis at IV doses (based on body surface area) less than the maximum recommended human daily dose.

Use in Lactation
There are no human or animal data on the excretion of terlipressin into milk or on the safety of terlipressin in infants. Hence, terlipressin should not be used in women who are breast-feeding.

Genotoxicity
Assays for gene mutation and chromosomal damage did not provide any evidence of a genotoxic potential for terlipressin.

Carcinogenicity
Carcinogenicity studies have not been performed.

INTERACTION WITH OTHER MEDICINES
Terlipressin increases the hypotensive effect of non-selective β-blockers on the portal vein. Concomitant treatment with drugs which are known to induce bradycardia (e.g. propofol, sufentanil) may lower the heart rate and cardiac output. These effects are due to reflexogenic inhibition of cardiac activity via the vagus nerve due to elevated blood pressure.

Terlipressin can trigger ventricular arrhythmias including "Torsade de pointes" (see PRECAUTIONS and ADVERSE EFFECTS). Therefore, extreme caution should be exercised in the use of terlipressin in patients with concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that may cause hypokalaemia or hypomagnesemia (e.g. some diuretics).

ADVERSE EFFECTS
The reporting of safety data rely on published literature and post marketing surveillance.
Clinical Trials

Three studies assessed safety as primary outcome in totally 1341 patients.

Caletti 1991, a prospective, uncontrolled observational study, enrolled 1258 patients. 21% of the patients experienced a side-effect. The side-effects reported were consistent with the known pharmacological actions of terlipressin.

Bruha 2009, a randomised, double blind study enrolled 25 patients that were randomised to either 5-day or 10-day treatment. Serum sodium and serum creatinine decreased in both arms during treatment, but rose again after discontinuation of treatment.

Solà 2010, a retrospective cohort study, included 58 patients. Over a 5 day treatment period 67% of the patients developed acute reduction in serum sodium. The hyponatraemia was found to develop rapidly after start of therapy, but was usually reversible with a median recovery time of 4 days after discontinuation of terlipressin.

Post-marketing Experience

The most commonly reported affected system organ classes were: cardiac disorders (66 reactions); vascular disorders (50 reactions); skin and subcutaneous tissue disorders (34 reactions); gastrointestinal disorders (30 reactions); metabolism and nutrition disorders (26 reactions) and nervous system disorders (22 reactions).

The table below lists the adverse effects reported for terlipressin in the post-marketing period.

<table>
<thead>
<tr>
<th>MedDRA System organ class Disorder</th>
<th>Common (&gt;1% &amp; &lt;10%)</th>
<th>Uncommon (&gt;0.1% &amp; &lt;1%)</th>
<th>Rare (&gt;0.01% &amp; &lt;0.1%)</th>
<th>Not known (cannot be estimated from the available data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>METABOLISM</td>
<td>Hyponatraemia if fluid not monitored;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td>Headache;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARDIAC</td>
<td>Bradycardia; Atrial Fibrillation; Ventricular Extrasystoles; Tachycardia; Chest pain; Myocardial Infarction; Fluid overload with pulmonary oedema; Ventricular fibrillation; Torsade de pointes; Cardiac failure;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VASCULAR</td>
<td>Peripheral vasoconstriction; Peripheral ischemia; Facial pallor; Hypertension; Intestinal ischaemia; Peripheral cyanosis; Hot flushes;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RESPIRATORY</td>
<td>Respiratory distress; Respiratory failure; Dyspnoea;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GASTROINTESTINAL</td>
<td>Transient abdominal cramps; Transient diarrhoea; Transient nausea; Transient vomiting;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SKIN AND SUBCUTANEOUS</td>
<td>Skin necrosis;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PREGNANCY, Puerperium AND Perinatal CONDITIONS</td>
<td>Uterine hypertonus; Decrease uterine blood flow;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GENERAL</td>
<td>Injection site necrosis;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DOSAGE AND ADMINISTRATION

GLYPRESSIN must only be administered intravenously.

Adults:
Initially an i.v. injection of 1.7 mg terlipressin (2 mg terlipressin acetate) is given every 4 hours. When the bleeding is under control the dose can be adjusted to 0.85 mg terlipressin (1 mg terlipressin acetate) i.v. every 4 hours. After the initial dose, the dose can also be adjusted to 0.85 mg (1 mg terlipressin acetate) i.v. every 4 hours in patients with body weight < 50 kg or if adverse effects occur. The treatment should not continue for more than 48 hours in total.

Children and Elderly:
No data are available regarding dosage recommendations in these patient populations.

Reconstitution:
GLYPRESSIN lyophilised powder is reconstituted by introducing the sterile diluent into the vial via the rubber stopper and mixing with the powder. The clear reconstituted solution must be used immediately after reconstitution. In the absence of compatibility studies GLYPRESSIN must not be mixed with other medicinal products.

GLYPRESSIN contains no antimicrobial agent. Product is for single use in one patient only. Discard any residue.

OVERDOSAGE
The recommended dose of 1.7 mg (equivalent to 2 mg terlipressin acetate) every 4 hours should not be exceeded as the risk of severe circulatory adverse effects is dose-dependent.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

PRESENTATION AND STORAGE CONDITIONS

Powder for Injection, vial:
White lyophilised powder in glass vial with rubber stopper, containing 0.85 mg terlipressin (equivalent to 1 mg terlipressin acetate), together with diluent in a 5 mL glass ampoule (equals ‘1 set’). Supplied in boxes containing 5 sets.

Storage conditions
Store below 25°C in the original carton to protect from light. Reconstituted drug should be used immediately.

NAME AND ADDRESS OF SPONSOR
Ferring Pharmaceuticals Pty Ltd
Suite 2, Level 1, Building 1
20 Bridge Street
Pymble NSW 2073
Australia

POISON SCHEDULE OF THE MEDICINE
Prescription Medicine (Schedule 4)

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (the ARTG)
14 May 2012
References:

Abid et al 2009:

Baveno V:
de Franchis, R (BAVENO V);

Bruha 2009:

Caletti 1991:

Escorsell et al 2000:

Freeman et al 1989:

Levacher et al 1995:

Söderlund et al 1990:

Solà 2010:

Walker et al 1986: